Elvire Pons-Tostivint

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

African American

Tyrosine Kinase

Small Cell Lung Cancer

Top Venues

Targeted oncology

Current oncology (Toronto, Ont.)

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Papazyan, Marc G Denis, Christine Sagan, Judith Raimbourg, Guillaume Herbreteau, Elvire Pons-Tostivint
Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib. Targeted oncology 19 (4) (2024)
Myung-Ju Ahn, Kentaro Tanaka, Luis G Paz-Ares, Robin Cornelissen, Nicolas Girard, Elvire Pons-Tostivint, David Vicente Baz, Shunichi Sugawara, Manuel Cobo, Maurice Pérol, Céline Mascaux, Elena V Poddubskaya, Satoru Kitazono, Hidetoshi Hayashi, Min Hee Hong, Enriqueta Felip Font, Richard Hall, Oscar Juan Vidal, Daniel Brungs, Shun Lu, Marina-Chiara Garassino, Michael J Chargualaf, Yong Zhang, Paul Howarth, Deise Uema, Aaron E Lisberg, Jacob M Sands, null null
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Thomas Papazyan, Marc G Denis, Christine Sagan, Judith Raimbourg, Guillaume Herbreteau, Elvire Pons-Tostivint
Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib. Targeted oncology (2024)
Thomas Papazyan, Marc G Denis, Christine Sagan, Judith Raimbourg, Guillaume Herbreteau, Elvire Pons-Tostivint
Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib. Targeted oncology 19 (4) (2024)
Koichi Goto, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang-We Kim, David Planchard, Myung-Ju Ahn, Egbert F Smit, Adrianus Johannes de Langen, Maurice Pérol, Elvire Pons-Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong Wan Kim, Chih-Hsi Kuo, James Chih-Hsin Yang, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A Janne
Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Laurent Mathiot, Guillaume Herbreteau, Siméon Robin, Charlotte Fenat, Jaafar Bennouna, Christophe Blanquart, Marc Guillaume Denis, Elvire Pons-Tostivint
HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature. Current oncology (Toronto, Ont.) 29 (5) (2022)
Elvire Pons-Tostivint, Jaafar Bennouna
Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine. Current oncology (Toronto, Ont.) 29 (10) (2022)
Elvire Pons-Tostivint, Alexandre Lugat, Jean-François Fonteneau, Marc Guillaume Denis, Jaafar Bennouna
STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact. Cells 10 (11) (2021)
Mathilde Bureau, Thierry Chatellier, Tanguy Perennec, Thomas Goronflot, Charlotte Greilsamer, Anne-Laure Chene, Raafet Affi, Eric Frampas, Jaafar Bennouna, Elvire Pons-Tostivint
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab. Cancer immunology, immunotherapy : CII (2021)